Alterity Therapeutics Management

Management criteria checks 3/4

Alterity Therapeutics' CEO is David Stamler, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is A$1.42M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $20.85K. The average tenure of the management team and the board of directors is 12.8 years and 18.5 years respectively.

Key information

David Stamler

Chief executive officer

AU$1.4m

Total compensation

CEO salary percentage	50.4%
CEO tenure	3.8yrs
CEO ownership	0.2%
Management average tenure	12.8yrs
Board average tenure	18.5yrs

Recent management updates

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

CEO Compensation Analysis

How has David Stamler's remuneration changed compared to Alterity Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$1m	AU$717k	-AU$19m
Mar 31 2024	n/a	n/a	-AU$16m
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$13m
Jun 30 2023	AU$2m	AU$731k	-AU$14m
Mar 31 2023	n/a	n/a	-AU$14m
Dec 31 2022	n/a	n/a	-AU$14m
Sep 30 2022	n/a	n/a	-AU$14m
Jun 30 2022	AU$2m	AU$658k	-AU$13m
Mar 31 2022	n/a	n/a	-AU$13m
Dec 31 2021	n/a	n/a	-AU$13m
Sep 30 2021	n/a	n/a	-AU$14m
Jun 30 2021	AU$979k	AU$606k	-AU$15m
Mar 31 2021	n/a	n/a	-AU$16m
Dec 31 2020	n/a	n/a	-AU$16m
Sep 30 2020	n/a	n/a	-AU$15m
Jun 30 2020	AU$625k	AU$625k	-AU$13m
Mar 31 2020	n/a	n/a	-AU$13m
Dec 31 2019	n/a	n/a	-AU$13m
Sep 30 2019	n/a	n/a	-AU$12m
Jun 30 2019	AU$548k	AU$548k	-AU$12m
Mar 31 2019	n/a	n/a	-AU$11m
Dec 31 2018	n/a	n/a	-AU$10m
Sep 30 2018	n/a	n/a	-AU$9m
Jun 30 2018	AU$630k	AU$504k	-AU$8m

Compensation vs Market: David's total compensation ($USD924.08K) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Stamler (63 yo)

3.8yrs

Tenure

AU$1,422,068

Compensation

Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Geoffrey Kempler	Co-Founder & Non-Executive Chairman	27yrs	AU$280.00k	0.28% $ 28.8k
David Stamler	Chief Executive Officer	3.8yrs	AU$1.42m	0.20% $ 20.9k
Abby Macnish Niven	CFO & Company Secretary	less than a year	no data	no data
Rudolph Tanzi	Chief Scientific Advisor and Member of Research & Development Advisory Board	12.8yrs	no data	no data
Steven Targum	Chief Medical Advisor	17.7yrs	no data	no data
Robert Cherny	Head of Research	17.6yrs	no data	no data

12.8yrs

Average Tenure

66yo

Average Age

Experienced Management: ATHE's management team is seasoned and experienced (12.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Geoffrey Kempler	Co-Founder & Non-Executive Chairman	27yrs	AU$280.00k	0.28% $ 28.8k
Rudolph Tanzi	Chief Scientific Advisor and Member of Research & Development Advisory Board	17.7yrs	no data	no data
Brian Meltzer	Non-Executive Independent Director	24.9yrs	AU$70.00k	0.14% $ 14.6k
Colin Masters	Member of Research & Development Advisory Board	17.7yrs	AU$241.36k	no data
Peter Marks	Non-Executive Independent Director	19.3yrs	AU$70.00k	0.14% $ 14.0k
Lawrence Gozlan	Non-Executive Director	13.3yrs	AU$70.00k	no data
Ira Shoulson	Chairman of Research & Development Advisory Board	no data	AU$78.76k	no data

18.5yrs

Average Tenure

69yo

Average Age

Experienced Board: ATHE's board of directors are seasoned and experienced ( 18.5 years average tenure).

Alterity Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Alterity Therapeutics Limited Announces Management Changes

Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024

Alterity Therapeutics Limited Announces Chief Financial Officer Changes

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022

Recent updates

Alterity Therapeutics Limited Announces Management Changes

Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024

Alterity Therapeutics Limited Announces Chief Financial Officer Changes

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Announces A New Composition of Matter Patent Allowed by the United States Patent and Trademark Office

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the Biomuse Natural History Study At the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Alterity Therapeutics Limited Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Alterity Therapeutics Announces Publication Demonstrating ATH434 Is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’S and Alzheimer’S

Alterity Therapeutics Limited Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Data Was Presented from the Company’s Biomarkers of Progression in Multiple System Atrophy Study

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

United States Patent and Trademark Office Issues Notice of Allowance for Patent Application of Alterity Therapeutics to Expand its Portfolio of Compounds for Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Announces New Publication Demonstrates ATH434 Is Neuroprotective

Alterity Therapeutics Limited announced that it has received AUD 17.17604 million in funding

Alterity Therapeutics Granted Anew Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Limited to Report First Half, 2021 Results on Feb 25, 2021

Alterity Therapeutics Limited Appoints Dr. David Stamler as CEO

Alterity Therapeutics names Dr. David Stamler as CEO

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Alterity Therapeutics Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study

Alterity Therapeutics Limited announced that it expects to receive AUD 35 million in funding

Alterity Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Alterity Therapeutics Limited to Report Fiscal Year 2020 Results on Sep 09, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age